Consequences of disclosing clinical trial results: Evidence from the food and drug administration amendments act
We examine how the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007, which requires additional disclosures regarding clinical trial results, impacts information asymmetry between the disclosing pharmaceutical firm and capital market participants, the general public, academics, and pr...
Saved in:
Main Authors: | BORVEAU, Thomas, CAPKUN, Vedran, WANG, Yin |
---|---|
格式: | text |
語言: | English |
出版: |
Institutional Knowledge at Singapore Management University
2020
|
主題: | |
在線閱讀: | https://ink.library.smu.edu.sg/soa_research/1838 https://ink.library.smu.edu.sg/context/soa_research/article/2865/viewcontent/SSRN_id3533305.pdf |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
相似書籍
-
Do firms respond to peer disclosures? Evidence from disclosures of clinical trial results
由: CAPKUN, Vedran, et al.
出版: (2023) -
Do firms respond to peer disclosures? Evidence from clinical trial disclosures
由: CAPKUN, Vedran, et al.
出版: (2021) -
Disclosure regulation: Past, present, and future
由: KOTHARI, S.P., et al.
出版: (2022) -
Disclosure and closeness: Effect of disclosing certain kinds of information about other individuals
由: Go, Jasper Alvin A., et al.
出版: (2009) -
The efficacy and safety of eperisone in patients with cervical spondylosis: Results of a randomized, double-blind, placebo-controlled trial
由: Bose, K.
出版: (2016)